Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled phase 2b trial in children
Hamtandi Magloire Natama(Research Institute of Health Sciences), Angela M. Minassian(National Institute for Health and Care Research), Katherine Skinner(University of Oxford), Dimitra Pipini(University of Oxford), Carole A. Long(National Institutes of Health), Jee-Sun Cho(University of Oxford), Alison M. Lawrie(University of Oxford), Edouard Ouédraogo(Institut de Recherche en Sciences de la Santé), Simon J. Draper(University of Oxford), Seyi Soremekun(London School of Hygiene & Tropical Medicine), Sarah E. Silk(University of Oxford), Umesh Shaligram(Serum Institute of India (India)), John Bradley(London School of Hygiene & Tropical Medicine), Florence Ouédraogo(Institut de Recherche en Sciences de la Santé), Massa dit Achille Bonko(Institut de Recherche en Sciences de la Santé), Hermann Sorgho(Institut de Recherche en Sciences de la Santé), Toussaint Rouamba(Institut de Recherche en Sciences de la Santé), Kazutoyo Miura(National Institutes of Health), Ousmane Traoré(Institut de Recherche en Sciences de la Santé), Jo Salkeld(University of Oxford), Rachel Roberts(University of Oxford), Halidou Tinto(Institut de Recherche en Sciences de la Santé), Lloyd D. W. King(University of Oxford), F. Konaté(Institut de Recherche en Sciences de la Santé), K. Carine Sonia Daboné(Institut de Recherche en Sciences de la Santé), Z. Michael John Compaoré(Institut de Recherche en Sciences de la Santé), Carolyn M. Nielsen(University of Oxford), Miguel Kafando(Institut de Recherche en Sciences de la Santé), Ababacar Diouf(National Institutes of Health)
Cited by 1
Related Papers
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
|Nature Medicine|2020|643
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial
|The Lancet|2021|457